Mattingly is an associate professor and vice chair of research in the Department of Pharmacotherapy at the University of Utah ...
The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...
Zacks.com on MSN14h
FTC Report Reveals PBM Practices Impacting Competition and Drug CostsThe FTC study examines the practices of PBMs to ensure fair competition and transparency. The FTC found that from 2017 to 2022, the three big PBMs imposed substantial price markups on 51 specialty ...
Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in ...
CVS Caremark, Express Scripts and OptumRx dramatically mark up specialty generic drugs to affiliated pharmacies, the Federal ...
The U.S. Federal Trade Commission on Tuesday published the second part of its investigation into how prescription drug ...
From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 ...
The Federal Trade Commission suggests that PBMs profit from specialty generic drugs such as those for cancer and HIV and ...
The nation's three largest pharmacy benefit managers have significantly marked up the prices of certain medicines, including ...
WASHINGTON >> The nation’s three largest pharmacy benefit managers have significantly marked up the prices of certain ...
As 2025 begins, we would like to reflect on last year’s regulatory developments in the biologics and biosimilars space. Here are ...
The Biden administration is poised to try to lower the amount of nicotine in tobacco products, an eleventh-hour effort that’s been years in the making.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback